预约演示

Nocion secures Series B funds to develop cough treatment

2024-03-05

交易

临床2期

Nocion has now secured a total of $122m in funding. Credit: staras / Shutterstock.com.

Nocion Therapeutics has secured $62m in a Series B financing round to advance its lead programme, Taplucanium dry powder for inhalation, into later-stage development for treating chronic cough.

Nocion Therapeuticsnd Monograph Capital led the funding round with contributions from new and currTaplucaniumrs, including Canaan Partners, Mass General Brigham Ventures, F-Prime chronic coughion BioCapital and Osage University Partners.

Arkin Bio Capitalsupport the evaluation of Taplucanium in a Phase IIb clinical trial.Canaan Partners Mass General Brigham Ventures Mission BioCapital

Nocion has now secured total funding of $12Taplucaniums inception in 2018.

Nocionrbach from Arkin Bio Capital and Freddie Dear from Monograph Capital will join the board of directors of Nocion.

See Also:Amylyx PArkin Bio Capitalles patent for treatment for neurodegenerative disease using bile acid and phNociontyrate

ORIC PharAmylyx Pharmaceuticalsnt for PLK4 inhibitors for canceneurodegenerative disease bile acid phenylbutyrate

Taplucanium, part of a new class of permanently charged sodium channel blockers, has been developed by Nocion to mute activated nociceptors.

ORIC Pharmaceuticalse implicated in sePLK4 inhibitors PLK4s conditions relcancero cough, itch and pain.

The molecule is designed to target activated or inflamed nociceptors with minimal off-target effects or systemic exposure.

Taplucaniumsm allows the asset to access the nociceptor through any open large pore channel where it inNocion the sodium channels that trigger the pathological cough response.

Preclinical models have demonstrated substantial antitussive effeccough Titchcaniupainnd initial safety and efficacy findings from early-stage trials suggest it could be effective for other cough indications besides chronic cough.

Nocion CEO Dr Richard Batycky stated: “We are grateful to our new and existing investors for their commitment to our lead programme in this challenging disease.

“This financing will enable us to evaluate Taplucanium in patients suffering from chronic cough. We will also be able to conduct additional toxicology and product development activities to be ready for Phase III clinical trials.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构